Takemura T, Takahashi S, Yoshikawa T, Kondo M
Dept. of Gastroenterology, Takeda Hospital.
Gan To Kagaku Ryoho. 2000 Jan;27(1):107-11.
The patient was a 80-year-old male with advanced gastric cancer (Type 3) accompanied by multiple liver and lymph node metastases. Histological findings in the stomach showed poorly differentiated adenocarcinoma. He had nausea, vomiting and anorexia due to pyloric stenosis, and was treated with 600 mg of UFT E granules/day orally for 5 consecutive days followed by 2 drug-free days (weekly-5 method), and 2 mg of lentinan intravenously twice a week. After 4 weeks of treatment, the primary tumor and metastatic lesions of the liver and lymph nodes were markedly reduced. His symptoms had completely disappeared along with lessening of the pyloric stenosis after 6 weeks of treatment. The patient survived for 7 months in a state of CR and PR. The adverse effects were very mild and negligible. A weekly-5 method of UFT, in comparison with conventional daily administration, may induce maximal antitumor effects with minimal adverse effects.
该患者为80岁男性，患有晚期胃癌（3型），伴有多处肝脏和淋巴结转移。胃部组织学检查结果显示为低分化腺癌。他因幽门狭窄出现恶心、呕吐和厌食症状，接受了口服UFT E颗粒剂600毫克/天，连续服用5天，随后停药2天（每周5天疗法），以及每周两次静脉注射2毫克香菇多糖的治疗。治疗4周后，肝脏和淋巴结的原发性肿瘤及转移病灶明显缩小。治疗6周后，他的症状完全消失，幽门狭窄也有所减轻。患者在完全缓解（CR）和部分缓解（PR）状态下存活了7个月。不良反应非常轻微，可忽略不计。与传统的每日给药相比，UFT的每周5天疗法可能以最小的不良反应诱导最大的抗肿瘤效果。
